Stem Cell Therapeutic and Research Reauthorization Act of 2025
United States119th CongressHR-5160House of Representatives
Updated: Jul 21, 2026
Summary
This bill, titled the "Stem Cell Therapeutic and Research Reauthorization Act of 2025," aims to extend the provisions of the original Stem Cell Therapeutic and Research Act of 2005, ensuring the continued operation and funding of critical stem cell-related programs. It reauthorizes the C.W. Bill Young Cell Transplantation Program , appropriating $33,009,000 annually for each of fiscal years 2027 through 2031 to maintain its financial stability. Additionally, the legislation extends the duration of the cord blood inventory program , which supports the collection and storage of cord blood units for therapeutic use, until fiscal year 2031 . This extension from its previous expiration in 2026 ensures the ongoing availability of vital resources for stem cell transplantation and research.
Bill texts
Timeline
Latest companion bill action
S-4109: Stem Cell Therapeutic and Research Reauthorization Act of 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
House of Representatives
Motion to reconsider laid on the table Agreed to without objection.
House of Representatives
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Senate